Can Gene-Edited immune cells tame Hard-to-Treat cancers?
NCT ID NCT07730125
First seen Jul 28, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostate cancer that has not responded to prior treatments. The goal is to see if the therapy is safe and to find the best dose for further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a gene-edited T regulatory cell therapy called CRG-150
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced breast or prostate cancers that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial, so the therapy may not work or could cause serious side effects like immune reactions or new malignancies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?